Flow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma
|
|
|
- Johnathan Curtis
- 8 years ago
- Views:
Transcription
1 Flow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma Maryalice Stetler-Stevenson, M.D., Ph.D. Flow Cytometry Unit, Laboratory of Pathology, DCS, NCI,NIH DEPARTMENT OF HEALTH & HUMAN SERVICES
2 Flow Cytometric Analysis of Hematolymphoid Neoplasia Standard of care-not research Guidelines available for medical indications Plays a vital role in diagnosis and subclassification Davis et al Bethesda International Consensus Recommendations on the Flow Cytometric Immunophenotypic Analysis of Hematolymphoid Neoplasia: Medical Indications, Clinical Cytometry. 72B:S5-S13, 2007
3 Flow Cytometric Diagnosis of Chronic Lymphocytic Leukemia (CLL) CLL is the most common leukemia in the western world Diagnosis is routinely made by a combination of flow cytometry, WBC and review of clinical history Flow cytometric diagnosis is accepted medical practice
4 Chronic Lymphocytic Leukemia (CLL) CLL Incidence: by country
5 Chronic Lymphocytic Leukemia (CLL) Guidelines for the Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute Working Group (NCI WG) 1996 guidelines: The diagnosis of CLL requires the presence of more than or equal to 5x 10 9 /L B lymphocytes (5000/µL) in the peripheral blood for the duration of at least 3 months. Clinical history is relevant Blood. 2008;111: )
6 Flow Cytometric Diagnosis of CLL : If detect by flow cytometry the presence of monoclonal B-cells with appropriate immunophenotype in the peripheral blood and at least 5x 10 9 /L B lymphocytes (5000/µL)*- Diagnosis is CLL If less than 5x 10 9 /L B lymphocytes (5000/µL)- Diagnosis is Monoclonal B-Cell Lymphocytosis Absolute lymphocyte count elevated: Monoclonal lymphocytosis with clinical lymphocytosis: Absolute lymphocyte count not elevated: Low count monoclonal lymphocytosis * duration of at least 3 months Clinical history and WBC results relevant
7 Flow Cytometric Diagnosis of CLL: Not a Chemistry Test But a Clinical Diagnosis SF pb_01_s-1.fcs SF pb_01_s-1.fcs Count % B-cells Count % B-cells CD19 PE HCL CD19 PE CLL SF pb_01_s-1.fcs SF pb_01_s-1.fcs Count % B-cells Polyclonal Count % B-cells Polyclonal CD19 PE CD19 PE Need more than a B-cell lymphocytosis for Diagnosis of CLL
8 Differential Diagnosis in CLL: Mantel Cell lymphoma Splenic Lymphoma with Villous Lymphocytes (SLVL) Lymphoplasmacytic lymphoma Follicular Lymphoma PLL HCL And if not determining lymphocytosis is B-cellother non-hodgkin s lymphomas, including T- cell.
9 Flow Cytometric Diagnosis of CLL: Not a Chemistry Test But a Clinical Diagnosis SF pb_08_b-5 new.fcs Can we just count CD5+ B-cells? SF pb_08_b-6+ K-p APC.fcs SF pb_08_b-5 new.fcs SF pb_08_b-6+ K-p.fcs CD5 PerCP Cy55 CLL CD5 PerCP Cy55 MCL CD5 PerCP Cy55 HCL CD5 PerCP Cy55 Polyclonal SF pb_08_b-5 new.fcs SF pb_08_b-6+ K-p.fcs SF pb_08_b-6+ K-p.fcs Lambda-p FITC CD5 PerCP Cy55 Gate 222 Lambda-p FITC Kappa-p APC Kappa-p APC
10 Flow Cytometric Diagnosis of CLL: Similar to Looking at H&E Slide CLL with vaguely nodular growth centers Follicular Lymphoma Reactive
11 Flow Cytometric Diagnosis of CLL : Appropriate Immunophenotype CD19+CD5+ CD5 v CD23 APC CD81 FITC CD23+ Dim to negative CD81 Dim CD20, dim CD Dim to negative CD79b Monoclonal CD22 PE CD79b PE Lambda-m PE CLL CD20 AH Kappa-m FITC
12 Flow Cytometric Diagnosis of CLL : Appropriate Immunophenotype CD5 APC CD23 APC CD81 FITC CD19+CD5+ Dim Partial CD23+ Moderate CD81 Moderate CD20&CD22 Moderate CD79b Monoclonal CD22 PE CD79b APC Lambda-m PE MCL CD20 AH7 Kappa-m FITC
13 CLL Diagnosis is Routinely Performed by Flow Cytometry: 5x 10 9 /L B-cells (5000/µL) At least 3 months duration Monoclonal Appropriate immunophenotype (CD19+, CD5+, CD23+, dim CD20+, dim CD22+, dim to negative CD79b, dim to negative CD81, CD43+, dim CD45+, dim surface immunoglobulin Diagnosis made by medical professional based upon identification of abnormal pattern and correlating this with history and other test results (WBC)
14 Flow Cytometry Used in Diagnosis and Sub-Classification of B- LPD Differentiation of reactive from clonal Sub-classification of CD5+ B-cell neoplasms: CLL, MCL, PLL, LCL, HCL, FL, Sub classification of CD10+ B-cell neoplasms: FL, Burkitt s. LCL, MCL, HCL Sub-classification of B-cell neoplasms with hairy/villous cytoplasmic borders HCL, HCLv, SLVL
15 Differentiation of reactive from clonal 422 SF pb_01_s-1.fcs Count % B-cells CD19 PE SF pb_08_b-6+ K-p.fcs SF pb_08_b-6+ K-p.fcs SF pb_08_b-6+ K-p.fcs CD5 PerCP Cy55 CD5 PerCP Cy55 Gate 222 Lambda-p FITC Kappa-p APC
16 Subclassification of B- Cell Neoplasms: CD5+ MCL: +CD5, +CD19, - CD23 (may be dim+), moderate CD20, CD22, sig, CD79b, CD81, CD45, CLL: +CD5, +CD19, +CD23, dim CD20, CD22, sig, CD79b, CD81, CD45 PLL and LCL CD5 CD5 CD19 CD19
17 Subclassification of B- Cell Neoplasms: CD10 Positivity FL: + CD10, dim CD19, +CD20, +CD22, +sig, +/-CD23, -CD5, -CD25, -CD11c, -CD103 Burkitt s: +CD10, moderate CD19, +CD20, +CD22, +sig, -CD23, -CD5 ALL:Immature +CD10, dim CD19, +CD22, +/-CD20, +TdT, -sig, +/-CD34 LCL and MCL CD10 CD10 CD19 CD19
18 Subclassification of B- Cell Neoplasms: Hairy/Villous Cytoplasmic Borders HCL + CD19, Bright CD20, Bright CD22, Bright CD25, Bright CD11c, CD103, CD123 HCLv + CD19, Bright CD20, Bright CD22, ++CD11c(can be moderate or dim), +CD103, - CD25, - or dimcd123 SLVL + CD19, Moderate CD20, Moderate CD22, +/- CD11c (dim when +), CD25-, CD103-, CD123- CD11c CD11c CD20 CD20
19 HCL CD19 PerCP Cy55 CD22 1:1 PE CD11c APC CD25 PE CD123 PE CD3 APC CD20 PerCP CD103 FITC CD20 PerCP CD20 PerCP HCLv CD19 PerCP Cy55 SLVL CD3 APC CD22 1:1 PE CD20 PerCP CD11c APC CD103 FITC CD25 PE CD20 PerCP CD123 PE CD20 PerCP CD19 PerCP Cy55 CD3 APC CD22 1:1 PE CD20 PerCP CD11c APC CD103 FITC CD25 PE CD20 PerCP CD123 PE CD19 PerCP Cy 55
20 Summary Flow cytometry is routinely used for diagnosis and sub-classification of B-cell neoplasia The diagnosis is made by a medical professional with intimate knowledge of normal immunophenotypic patterns Diagnosis is based upon recognition of an abnormal pattern, not a single value, similar to evaluation of morphology. Flow cytometric results are correlated with clinical history and the results of other tests for the diagnosis
Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms
Clin Lab Med 27 (2007) 487 512 Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms Fiona E. Craig, MD Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine,
Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA
Interesting Case Review Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA History 63 y/o male with h/o CLL for 10 years Presents with worsening renal function and hypercalcemia
Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms. Dr. Douaa Mohammed Sayed
Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms Dr. Douaa Mohammed Sayed Small lymphocytic lymphoma/b-cell chronic lymphocytic leukemia BMB: nodular, interstitial, diffuse or a combination
Flow Cytometry for Everyone Else Susan McQuiston, J.D., MLS(ASCP), C.Cy.
Flow Cytometry for Everyone Else Susan McQuiston, J.D., MLS(ASCP), C.Cy. At the end of this session, the participant will be able to: 1. Describe the components of a flow cytometer 2. Describe the gating
LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons
LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:
B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2008 WHO Classification of Lymphoid Neoplasms: Small B-Cell Neoplasms Chronic lymphocytic leukemia/small lymphocytic lymphoma B-cell prolymphocytic leukemia Splenic marginal zone B-cell lymphoma Hairy
for Leucocyte Immunophenotyping Leukaemia Diagnosis Interpretation All Participants Date Issued: 08-September-2014 Closing Date: 26-September-2014
for Leucocyte Immunophenotyping Leukaemia Interpretation All Participants Participant: 4xxxx Trial No: 141502 Date Issued: 08-September-2014 Closing Date: 26-September-2014 Trial Comments This was an electronic
Non-Hodgkin s Lymphoma
Non-Hodgkin s Lymphoma Luis Fayad, MD Assistant Professor Clinical Medical Director Lymphoma/Myeloma Department Non-Hodgkin s Lymphoma Non-Hodgkin s lymphomas (NHL) are a heterogeneous group of malignant
Malignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
Pathology No: SHS-CASE No. Date of Procedure: Client Name Address
TEL #: (650) 725-5604 FAX #: (650) 725-7409 Med. Rec. No.: Date of Procedure: Sex: A ge: Date Received: Date of Birth: Account No.: Physician(s): Client Name Address SPECIMEN SUBMITTED: LEFT PIC BONE MARROW,
Utility of flow cytometric κ and λ light chain analysis of peripheral blood
JBUON 2015; 20(5): 1322-1326 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Utility of flow cytometric κ and λ light chain analysis of peripheral
About B Cell Lymphomas Groupmeeting Klipp/Spang, December 09 2002 Dennis Kostka Max-Planck-Institute for Molecular Genetics Computational Molecular Biology Berlin 1 Overview Short History of Lymphoma Classification
Leukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
Outline of lecture. Disclosures. Current Issues in Practical Hematopathology: Diagnosis of Bone Marrow Lymphomas
Current Issues in Practical Hematopathology: Diagnosis of Bone Marrow Lymphomas Disclosures I have no disclosures relevant to the content of this lecture Robert P Hasserjian, MD Associate Professor Massachusetts
DELPHI 27 V 2016 CYTOMETRY STRATEGIES IN THE DIAGNOSIS OF HEMATOLOGICAL DISEASES
DELPHI 27 V 2016 CYTOMETRY STRATEGIES IN THE DIAGNOSIS OF HEMATOLOGICAL DISEASES CLAUDIO ORTOLANI UNIVERSITY OF URBINO - ITALY SUN TZU (544 b.c. 496 b.c) SUN TZU (544 b.c. 496 b.c.) THE ART OF CYTOMETRY
Monoclonal B-Cell Lymphocytosis
Monoclonal B-Cell Lymphocytosis Identification of parameters involved in the pathogenesis and in a higher risk of malignant transformation Belen Espinosa Degree project in biology, Master of science (2
Hematology Morphology Critique
Survey Slide: History: 60-year-old female presenting with pneumonia Further Laboratory Data: Hgb : 90 g/l RBC : 2.92 10 12 /L Hct : 0.25 L/L MCV : 87 fl MCH : 30.8 pg MCHC : 355 g/l RDW : 17.7 % WBC :
MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)
MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.
Lymphoma Diagnosis and Classification
Lymphoma Diagnosis and Classification By Atef Shrit, MD, Pathology B- and T/NK-cell lymphomas are clonal neoplasms of immature and mature B-lymphocytes, T-lymphocytes or natural killer cells at various
Subtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand.
1 2 3 4 The FAB assigns a cut off of 30% blasts to define AML and relies predominantly on morphology and cytochemical stains (MPO, Sudan Black, and NSE which will be discussed later). Subtypes of AML follow
The NIAID Flow Cytometry Advisory Committee; the Guidelines Subcommittee
January, 1999 From: To: Subject: The NIAID Flow Cytometry Advisory Committee; the Guidelines Subcommittee NIAID DAIDS Flow Cytometry Laboratories Comparison study information for labs wishing to switch
Flow Cytometry A Guide for Data Analysis
Flow Cytometry A Guide for Data Analysis Last revisions 12 Aug 2013 Ron Lee, M.D. Introduction This guide is intended to provide a basic overview of clinical flow cytometry data analysis. General Principles
Bone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital
Bone Marrow Evaluation for Lymphoma Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital Indications One of the most common indications for a bone marrow biopsy is to evaluate for malignant lymphoma.
Lymphoplasmacytic Lymphoma. Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH
Lymphoplasmacytic Lymphoma versus IGM Multiple Myeloma Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH Hematology consult patient 48 yo woman presents to ER with nonspecific complaints:
Updating the 2008 WHO Classification of Small B cell lymphomas Elias Campo
Updating the 2008 WHO Classification of Small B cell lymphomas Elias Campo Hospital Clinic, University of Barcelona Barcelona, Spain Disclosure of Relevant Financial Relationships Dr. ELIAS CAMPO declares
Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham
Lymphoid Neoplasms Sylvie Freeman Department of Clinical Immunology, University of Birmingham Incidence of Haematological Malignancies UK2001 (CRUK) Malignancy New Cases All Cancers 271,000 Leukaemia 6,760
Main Street Planning Group 180 East Main Street Suite 110 Patchogue, NY 11772 Tel: 631.647.4694 Fax: 631.647.4697 MainStreetPlanningGroup.
Main Street Planning Group 180 East Main Street Suite 110 Patchogue, NY 11772 Tel: 631.647.4694 Fax: 631.647.4697 MainStreetPlanningGroup.com Presented by Ted Mageau Ted@MainStreetPlanningGroup.com Life
International Beryllium Conference, Montreal, Canada March 10, 2005
Alternative Lymphocyte Proliferation Tests: BrdU and Flow Cytometry Based Tests International Beryllium Conference, Montreal, Canada March 10, 2005 Tim K. Takaro Department of Environmental and Occupational
Waldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP
Waldenström Macroglobulinemia: The Burning Questions IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP Are my kids going to get this? Familial seen in approximately 5 10% of all CLL patients and can be associated
chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
Pulling the Plug on Cancer Cell Communication. Stephen M. Ansell, MD, PhD Mayo Clinic
Pulling the Plug on Cancer Cell Communication Stephen M. Ansell, MD, PhD Mayo Clinic Why do Waldenstrom s cells need to communicate? Waldenstrom s cells need activating signals to stay alive. WM cells
WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED?
WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED? Which test should be submitted? The answer to this depends on the clinical signs, and the diagnostic question you are asking. If
What to know about the B-cell neoplasms Steven H. Swerdlow, M.D.
What to know about the B-cell neoplasms Steven H. Swerdlow, M.D. Bullet points and key words The 2008 Revised WHO monograph on Tumours of the haematopoietic and lymphoid tissues includes many changes among
SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015
LEUKEMIA Response in Acute Myeloid Leukemia (AML) Response criteria in Acute Myeloid Leukemia for SWOG protocols is based on the review article Diagnosis and management of acute myeloid leukemia in adults:
PERIPHERAL SMEARS: THE PRIMARY DIAGNOSTIC TOOL PART II IRMA PEREIRA, MT(ASCP)SH
PERIPHERAL SMEARS: THE PRIMARY DIAGNOSTIC TOOL PART II IRMA PEREIRA, MT(ASCP)SH WORKSHOPS FOR LABORATORY PROFESSIONALS As a service to the medical profession and to the general public, the American Society
Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY
Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular
Stepcount. Product Description: Closed transparent tubes with a metal screen, including a white matrix at the bottom. Cat. Reference: STP-25T
Product Description: Closed transparent tubes with a metal screen, including a white matrix at the bottom Cat. Reference: STP-25T Reagent provided:: 25 Stepcount tubes for 25 test INTENDED USE. Immunostep
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,
Anaplastic large cell lymphoma (ALCL) accounts for approximately
Original Articles Flow Cytometric Immunophenotyping of Anaplastic Large Cell Lymphoma Tariq Muzzafar, MD; Eric X. Wei, MD, PhD; Pei Lin, MD; L. Jeffrey Medeiros, MD; Jeffrey L. Jorgensen, MD, PhD Context.
Anti-HCV therapy in HCV-related NHL
Gabriele Pozzato M.D. University of Trieste Anti-HCV therapy in HCV-related NHL Questions about HCV+ in NHL Is the NHL related with HCV infection? Which is the best therapeutic strategy? Is the antiviral
What Leukemia Is. Understanding blood
Leukemia is a malignant disease of the blood-forming cells. It involves white blood cells that do not mature and that reproduce too rapidly. Eventually, they replace the normal bone marrow, leaving insufficient
FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
Reference Range: 0.5-1.6 mmol/l (arterial) 0.7-2.1 mmol/l (venous) CPT Code: 83605
LACTIC ACID Fasting, arterial specimen preferred. Please note whether arterial or venous. 0.5 ml heparinized plasma. Green top or PST must be drawn, placed on ice, and spun within 15 minutes. Immediately
Methodology for Automatic Classification of Atypical Lymphoid Cells from Peripheral Blood Cell Images
Methodology for Automatic Classification of Atypical Lymphoid Cells from Peripheral Blood Cell Images Edwin Santiago Alférez Baquero Supervised by Dr. José Rodellar Dra. Anna Merino Department of Applied
Immunohistochemical classification of malignant lymphomas
Immunohistochemical classification of malignant lymphomas Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Thanks to Jan Klos Important issues Distinction from non-hematopoietic neoplasms
Hematopathology VII Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, And Hairy Cell Leukemia
John L. Kennedy, M.D. UIC College of Medicine Associate Professor of Clinical Pathology M2 Pathology Course Lead Pathologist, VA Chicago Health Care System Lecture #43 Phone: (312) 569-6690 Thursday, November
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib
Cancer. 9p21.3 deletion. t(12;21) t(15;17)
CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)
Oncology Best Practice Documentation
Oncology Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Solid Tumors Lymphomas Leukemias Myelodysplastic Syndrome Pathology Findings
Genomic Analysis of Mature B-cell Malignancies
Genomic Analysis of Mature B-cell Malignancies Update and Lessons Learned Omar Abdel-Wahab, MD Memorial Sloan Kettering Cancer Center Human Oncology and Pathogenesis Program and Leukemia Service Disclaimer:
Standardization, Calibration and Quality Control
Standardization, Calibration and Quality Control Ian Storie Flow cytometry has become an essential tool in the research and clinical diagnostic laboratory. The range of available flow-based diagnostic
Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
IQ Corporation c/o Harold G. Haines, Ph.D. President SEP 1 f 2002 South Florida BioAssociates, Inc. 11511 SW 127h Street Miami, Florida 33 176
**,lo 4 DEPARTMENT OF HEALTH & HUMAN SERVICES IQ Corporation c/o Harold G. Haines, Ph.D. President SEP 1 f 2002 South Florida BioAssociates, Inc. 11511 SW 127h Street Miami, Florida 33 176. Food and Drug
Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data
(Form 2018) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data Form. E-mail comments regarding the content
Diagnostika onkohematologických ochorení pomocou prietokovej cytometrie Jozef Smolka Beckman Coulter Slovenská republika s.r.o.
Diagnostika onkohematologických ochorení pomocou prietokovej cytometrie Jozef Smolka Beckman Coulter Slovenská republika s.r.o. 29. máj 2013, KLINICKÁ BIOCHÉMIA, s.r.o. Žilina, Medicínske laboratórium
Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
Immunophenotypic Analysis of Peripheral T-Cell Neoplasms A Multiparameter Flow Cytometric Approach
Hematopathology / FLOW CYTOMETRY OF T-CELL NEOPLASMS Immunophenotypic Analysis of Peripheral T-Cell Neoplasms A Multiparameter Flow Cytometric Approach Saba Jamal, MD, * Louis J. Picker, MD, * Deborah
Mantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
Large Cell Lymphoma Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma A Flow Cytometric Analysis of Seven Cases
Hematopathology / IMMUNOPHENOTYPE OF RICHTER SYNDROME Large Cell Lymphoma Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma A Flow Cytometric Analysis of Seven Cases Steven H. Kroft,
Fluorescence Compensation. Jennifer Wilshire, PhD jennifer@flowjo.com
Fluorescence Compensation Jennifer Wilshire, PhD jennifer@flowjo.com Outline 1. Compensation Basics 2. Practical Applications -selecting comp controls (cells, stains?) 3. Multicolor Issues -spreading due
Chronic lymphocytic EBMT Slideleukemia. University of Heidelberg, Germany March 22, 2010. The European Group for Blood and Marrow Transplantation
Chronic lymphocytic EBMT Slideleukemia template Peter Barcelona Dreger Chairman, CLL 7 February subcommittee 2008 University of Heidelberg, Germany March 22, 2010 The European Group for Blood and Marrow
CD5-positive, Small B-Cell Lymphoproliferative Disorders: Aberrant Findings of CLL/SLL and MCL
North American Journal of Medicine and Science Oct 2010 Vol 3 No.4 181 CD5-positive, Small B-Cell Lymphoproliferative Disorders: Aberrant Findings of CLL/SLL and MCL Youjun Hu, MD, Marc Golightly, PhD
Bo Feng, Jeffrey L Jorgensen, Dan Jones, Su S Chen, Ying Hu, L Jeffrey Medeiros and Sa A Wang
284 & 21 USCAP, Inc. All rights reserved 893-3952/1 $32. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vb chain antibodies and
Update on Diagnosis and Treatment of Lymphoma
Update on Diagnosis and Treatment of Lymphoma Wei Ai, M.D., Ph.D. Assistant Clinical Professor of Medicine May 2010 Cancer Incidence New Cancer Cases Lymphoma 63,000 - NHL 53,600 - HL 75,00 Cancer Death
Multiple Myeloma and Colorectal Cancer
Multiple Myeloma and Colorectal Cancer From Systems Immunology to Single Cells Leo Hansmann Mark M. Davis Lab Department of Microbiology&Immunology Stanford University Multiple Myeloma Monoclonal disease
123count ebeads Catalog Number: 01-1234 Also known as: Absolute cell count beads GPR: General Purpose Reagents. For Laboratory Use.
Page 1 of 1 Catalog Number: 01-1234 Also known as: Absolute cell count beads GPR: General Purpose Reagents. For Laboratory Use. Normal human peripheral blood was stained with Anti- Human CD45 PE (cat.
1++ 47.00 0.1+ 104.00 5++ 26.00 1+ 484.00 10++ 20.00 2+ 363.00 20++ 15.25 5+ 244.00 50++ 10.15 10+ 183.00 100++ 7.60 500++ 4.15
Since April 1991, the International Blood Group Reference Laboratory (IBGRL) has had a range of monoclonal antibodies for immunohaematological research marketed under the name "IBGRL Research Products".
Novel Use of the BD FACS TM SPA to Automate Custom Monoclonal Antibody Panel Preparations for Immunophenotyping
Cytometry Part B (Clinical Cytometry) 66B:40 45 (2005) TECHNICAL INNOVATION Novel Use of the BD FACS TM SPA to Automate Custom Monoclonal Antibody Panel Preparations for Immunophenotyping Abigail S. Kelliher,
INFECTIOUS MONONUCLEOSIS DIAGNOSTIC POTENTIALS
Journal of IMAB - Annual Proceeding (Scientific Papers) 2008, book 1 INFECTIOUS MONONUCLEOSIS DIAGNOSTIC POTENTIALS Milena Karcheva, Tz. Lukanov *, S. Gecheva *, V. Slavcheva **, G. Veleva *, R. Nachev
Application Note 10. Measurement of Cell Recovery. After Sorting with a Catcher-Tube-Based. Cell Sorter. Introduction
Application Note 10 Measurement of Cell Recovery After Sorting with a Catcher-Tube-Based Cell Sorter Introduction In many experiments using sorted cells, it is important to be able to count the number
Multicolor Flow Cytometry: Setup and Optimization on the BD Accuri C6 Flow Cytometer
Multicolor Flow Cytometry: Setup and Optimization on the BD Accuri C6 Flow Cytometer Presented by Clare Rogers, MS Senior Marketing Applications Specialist BD Biosciences 23-13660-00 Webinar Overview Multicolor
Hairy Cell Leukemia Facts
No. 16 in a series providing the latest information for patients, caregivers and healthcare professionals www.lls.org Information Specialist: 800.955.4572 Highlights l Hairy cell leukemia (HCL) is a chronic
Immunophenotyping. Alberto Orfao, MD, PhD
Immunophenotyping Alberto Orfao, MD, PhD Introduction Immunophenotyping of biological samples refers to the use of immunological tools (e.g. monoclonal and/or polyclonal antibodies) for the specific detection
Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
Immuno-Oncology Model Application in the Preclinical Treatment Setting
Immuno-Oncology Model Application in the Preclinical Treatment Setting Maryland Franklin, Ph.D. Senior Director, Scientific Development mfranklin@molecularimaging.com July 22, 2015 Tumor Models Conference
Chromosome 6 Abnormalities Associated with Prolymphocytic Acceleration in Chronic Lymphocytic Leukemia* f
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 28, No. 1 Copyright 1998, Institute for Clinical Science, Inc. Chromosome 6 Abnormalities Associated with Prolymphocytic Acceleration in Chronic Lymphocytic
Treatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
Multicolor Bead Flow Cytometry Standardization Heba Degheidy MD, PhD, QCYM DB/OSEL/CDRH/FDA Manager of MCM Flow Cytometry Facility
Multicolor Bead Flow Cytometry Standardization Heba Degheidy MD, PhD, QCYM DB/OSEL/CDRH/FDA Manager of MCM Flow Cytometry Facility The mention of commercial products, their sources, or their use in connection
Principles of Flowcytometry
Objectives Introduction to Cell Markers: Principles of Flowcytometry Michelle Petrasich NZIMLS Scientific Meeting August 24, 2010, Paihia What are cell markers How do we detect them Production of Monoclonal
BD FACSCalibur. The flow cytometer for your routine cell analysis needs
BD FACSCalibur The flow cytometer for your routine cell analysis needs A system with a rich application basis and a modular approach that continues to meet evolving needs of cell analysis worldwide. The
Using the BD TM Cytometer Setup and Tracking (CS&T) System for Instrument Characterization and Performance Tracking
Using the BD TM Cytometer Setup and Tracking (CS&T) System for Instrument Characterization and Performance Tracking Mark KuKuruga Senior Technical Applications Specialist BD Biosciences 23-14462-00 Outline
CAR T cell therapy for lymphomas
CAR T cell therapy for lymphomas Sattva S. Neelapu, MD Associate Professor and Deputy Chair ad interim Department of Lymphoma and Myeloma UT MD Anderson Cancer Center, Houston, TX CAR T cell therapy What
Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.
Chronic Lymphocytic Leukemia AAIM Triennial October 2012 Susan Sokoloski, M.D. Case Study 57 year old male, trial application for $1,000,000 Universal Life coverage Cover letter from sales agent indicates
Things You Don t Want to Miss in Multiple Myeloma
Things You Don t Want to Miss in Multiple Myeloma Sreenivasa Chandana, MD, PhD Attending Hematologist and Medical Oncologist West Michigan Cancer Center Assistant Professor, Western Michigan University
In non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
Frequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
David Loew, LCL MabThera
MabThera The star continues to rise David Loew, LCL MabThera MabThera the star continues to raise Group sales (CHF bn) 4,5 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 2001 2002 2003 2004 2005 Outstanding clinical
NEW YORK STATE CYTOHEMATOLOGY PROFICIENCY TESTING PROGRAM Glass Slide Critique ~ November 2010
NEW YORK STATE CYTOHEMATOLOGY PROFICIENCY TESTING PROGRAM Glass Slide Critique ~ November 2010 Slide 081 Available data: 72 year-old female Diagnosis: MDS to AML WBC 51.0 x 10 9 /L RBC 3.39 x 10 12 /L
Canine lymphoproliferative disorders often present
J Vet Intern Med 2008;22:596 601 Canine Lymphoproliferative Disease Characterized by Lymphocytosis: Immunophenotypic Markers of Prognosis M.J. Williams, A.C. Avery, S.E. Lana, K.R. Hillers, A.M. Bachand,
Welcome to More Choice BD Analyte Specific Reagent (ASR) Catalog
Welcome to More Choice BD Analyte Specific Reagent (ASR) Catalog 3 rd Edition Contents ASR Cell Lineage 3 15 Marker 16 25 Flow cytometry allows you to analyze multiple parameters simultaneously and by
2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant
2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant Guidelines & General Instructions for Application KEY DATES: Application Release Date: December 12, 2012 Application Deadline: February
Introduction to Flow Cytometry
Introduction to Flow Cytometry presented by: Flow Cytometry y Core Facility Biomedical Instrumentation Center Uniformed Services University Topics Covered in this Lecture What is flow cytometry? Flow cytometer
WHOLE BLOOD LYSING SOLUTION FOR FLOW CYTOMETRIC APPLICATIONS
FOR IN-VITRO DIAGNOSTIC USE INVITROGEN CAL-LYSE TM Lysing Solution WHOLE BLOOD LYSING SOLUTION FOR FLOW CYTOMETRIC APPLICATIONS CAL-LYSE TM CATALOG No. GAS-010 250 tests 25 ml CATALOG No. GAS-010S-100
AWLP Lymphoma Course and Workshop 9-10 November 2011 Hilton, Cardiff City Centre PROGRAMME
AWLP Lymphoma Course and Workshop 9-10 November 2011 Hilton, Cardiff City Centre PROGRAMME Sponsored by This course and workshop are designed for more experienced trainees in Histopathology, Haematology
Too Many B Cells: Chronic Lymphocytic Leukemia and the Role of Flow Cytometry
Too Many B Cells: Chronic Lymphocytic Leukemia and the Role of Flow Cytometry by Debby R. Walser-Kuntz Biology Department Carleton College, Northfield, MN Taylor goes in to see her doctor, Dr. Chavez,
Corporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
Summary & Conclusion
The prognostic value of angiogenesis markers in patients with non-hodgkin lymphoma. Summary & Conclusion The current study aims to asses the prognostic value of some angiogenesis markers in patients with
Introduction to Flow Cytometry
Outline Introduction to Flow Cytometry Basic Concept of Flow Cytometry Introduction to Instrument Subsystems Daisy Kuo Assistant Product Manager E-mail: daisy_kuo@bd.com BDBiosciences Application Examples